[
    [
        {
            "time": "2020-11-00",
            "original_text": "公司于2020年11月获得西格列汀二甲双胍片（I）（50/500mg）的药品注册证书，西格列汀二甲双胍片（50/850mg）已申报生产",
            "features": {
                "keywords": [
                    "西格列汀二甲双胍片",
                    "药品注册证书",
                    "申报生产"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "公司于2020年11月获得西格列汀二甲双胍片（I）（50/500mg）的药品注册证书，西格列汀二甲双胍片（50/850mg）已申报生产",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020-09-00",
            "original_text": "公司于2020年9月获得蓬莱诺康药业有限公司的腺苷注射液产品，今年已完成上市许可持有人变更，并已正式由中美华东销售团队负责药学服务及市场推广，今年销售情况良好，已超过该产品2020年销售收入。",
            "features": {
                "keywords": [
                    "腺苷注射液",
                    "上市许可持有人变更",
                    "销售情况良好"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "公司于2020年9月获得蓬莱诺康药业有限公司的腺苷注射液产品，今年已完成上市许可持有人变更，并已正式由中美华东销售团队负责药学服务及市场推广，今年销售情况良好，已超过该产品2020年销售收入。",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-27",
            "original_text": "2021年第三季度报告将于10月27日发布",
            "features": {
                "keywords": [
                    "第三季度报告",
                    "发布"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "财务"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2021年第三季度报告将于10月27日发布",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-00",
            "original_text": "利拉鲁肽注射液减肥适应症，目前已经完成Ⅲ期临床受试者入组，正在进行随访，计划于2021年底左右开展上市申报工作",
            "features": {
                "keywords": [
                    "利拉鲁肽注射液",
                    "减肥适应症",
                    "Ⅲ期临床",
                    "上市申报"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "利拉鲁肽注射液减肥适应症，目前已经完成Ⅲ期临床受试者入组，正在进行随访，计划于2021年底左右开展上市申报工作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-00-00",
            "original_text": "“母子公司之争”即将落幕，核心公司失控后的华东医药路在何方？",
            "features": {
                "keywords": [
                    "母子公司之争",
                    "核心公司失控"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "公司治理"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "“母子公司之争”即将落幕，核心公司失控后的华东医药路在何方？",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-00-00",
            "original_text": "医美行业周报：医用敷料贴赛道高景气 国产品牌占据优势",
            "features": {
                "keywords": [
                    "医美行业",
                    "医用敷料贴",
                    "高景气",
                    "国产品牌"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医美行业周报：医用敷料贴赛道高景气 国产品牌占据优势",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]